International Cardiovascular Conference Highlights Emerging Therapies in Heart Disease
On October 3, international leaders in heart disease gathered at the Fontainebleau Hotel on Miami Beach for the M3 2011 International Cardiovascular Conference.
Among the highlights of the three-day conference were UM research trials on percutaneous aortic valve replacement and renal denervation for resistant hypertension. Attendees also got a glimpse of future interventional tools through a summary of first-in-man, pre-FDA data.
“This conference was truly like no other,” said Eduardo de Marchena, M.D., associate dean of international medicine and chair of University of Miami Medical Group, who also was course director along with Robert M. Bersin, M.D., medical director of endovascular services for Seattle Cardiology and Swedish Medical Center. “World leaders in cardiology all came together bringing new and emerging innovations that will give us even more tools to care for patients.”
This was the first time the UM “Masters in Repair of Structural Heart Disease” conference and the Society for Cardiovascular Angiography and Intervention’s “Meeting of the Americas” converged to form the international conference, which attracted more than 300 medical professionals and scientists from 14 countries. Multiple UM cardiovascular faculty, including Pascal J. Goldschmidt, M.D., Senior Vice President for Medical Affairs and Dean and CEO of UHealth, and William O’Neill, M.D., executive dean for clinical affairs and chief medical officer of UHealth, lectured at the conference.
The next conference is planned for 2013.